Eating

Foundayo (Orforglipron): The Daily GLP-1 Pill, Trial Results, Price and How It Compares to the Wegovy Pill

Jeff Zorn · · 14 min read

Share

By Jeff Zorn, founder of Zornava. Former college basketball player, degree in exercise science and nutrition, two years on GLP-1 medications. My experience, not medical advice. Talk to your prescriber or a registered dietitian about your own situation.

Published · Last reviewed

Short answer: Orforglipron is Eli Lilly's once-daily GLP-1 pill, sold in the US as Foundayo. The FDA approved it on April 1, 2026 for chronic weight management in adults with obesity, or overweight with at least one weight-related condition.[1][2] Unlike oral semaglutide, its label says to take it "with or without food," with no fasting or water limit.[2] In its main trial, body weight fell by an average of 11.2% over 72 weeks on the top dose, against 2.1% on placebo.[3]

New to eating less? Start with what to eat when you're eating less, the guide the rest of Lighter Days builds on.

This page sets out what is known as of November 13, 2026: what orforglipron is, how it differs from the two oral semaglutide tablets, what each trial found, the adverse events by dose, what the label says, and what it costs. It ends with the part that applies to every GLP-1 medication: eating enough when appetite is small.

General information, not medical advice. Whether any of these medications suits you, and at what dose, is a decision for you and your prescriber.

Orforglipron vs the Wegovy pill vs Rybelsus

Orforglipron (Foundayo) Oral semaglutide 25 mg (Wegovy pill) Oral semaglutide (Rybelsus)
Maker Eli Lilly Novo Nordisk Novo Nordisk
What it is Small-molecule GLP-1 receptor agonist, not a peptide[3] Semaglutide, a peptide, in tablet form[4] Semaglutide, a peptide, in tablet form[5]
Form Tablet once a day[2] Tablet once a day[4] Tablet once a day[5]
Food and water rules on the label "With or without food"; no water limit or waiting time[2] Empty stomach in the morning, up to 4 ounces of water, then wait at least 30 minutes before eating, drinking or other oral medicines[4] Same as the Wegovy pill: empty stomach, up to 4 ounces of water, wait at least 30 minutes[5]
US status (November 2026) Approved April 1, 2026 for chronic weight management; type 2 diabetes application under FDA evaluation[1][6] Approved December 22, 2025 for chronic weight management[7] Approved for blood sugar control in adults with type 2 diabetes[5]
Headline result ATTAIN-1: body weight −11.2% at 72 weeks on the top dose, vs −2.1% on placebo[3] OASIS 4: −13.6% at 64 weeks, vs −2.2% on placebo[8] ACHIEVE-3: HbA1c −1.47 points on 14 mg at 52 weeks, vs −1.91 on orforglipron 36 mg[9]

Read the last row with care. ATTAIN-1 and OASIS 4 are different trials, in different people, over different lengths of time, so their numbers cannot be lined up as a contest. No trial comparing orforglipron directly with the 25 mg Wegovy pill for body weight has reported. The one head-to-head trial, ACHIEVE-3, compared orforglipron with Rybelsus doses of oral semaglutide in type 2 diabetes. All the figures above are treatment-regimen results, which count everyone randomized whether or not they kept taking the drug.

What is orforglipron?

Orforglipron is an oral small-molecule GLP-1 receptor agonist: a compact chemical drug that activates the same receptor as semaglutide, rather than a peptide modeled on the GLP-1 hormone itself.[3] Semaglutide is a peptide, and its tablets carry strict fasting rules.[4][5] Orforglipron is the second GLP-1 pill approved for chronic weight management in the US, after the Wegovy pill,[7] and the first new molecular entity approved under the FDA's National Priority Voucher program.[1]

One unusual line in its label: the boxed warning about thyroid C-cell tumors, which the semaglutide and tirzepatide labels also carry,[4][10] notes that orforglipron "is not pharmacologically active in rats or mice and did not produce tumors in rodents." The warning stays anyway, and the drug is not to be used by anyone with a personal or family history of medullary thyroid carcinoma or with MEN 2.[2]

If you are comparing it with the injectable medicines, our semaglutide and tirzepatide guides cover those, and retatrutide covers Lilly's investigational triple agonist.

Is orforglipron FDA approved?

Yes, for chronic weight management, since April 1, 2026, under the brand name Foundayo. The dated record:

  • November 6, 2025: The FDA awards orforglipron for obesity a Commissioner's National Priority Voucher, a pilot program meant to speed review.[11]
  • December 18, 2025: Lilly reports that it has submitted a new drug application for obesity to the FDA.[12]
  • April 1, 2026: The FDA approves Foundayo, 50 days after filing and 294 days before the application's standard goal date of January 20, 2027. The FDA called it the fastest approval of a new molecular entity since 2002.[1]
  • Second quarter of 2026: Lilly submits orforglipron for type 2 diabetes in the US.[6] We found no FDA decision on that application as of November 13, 2026.
  • August 10, 2026: The UK's MHRA authorises it for weight management and type 2 diabetes, the first in Europe.[13]
  • October 16, 2026: The European Medicines Agency's committee recommends approval for weight management and type 2 diabetes; the European Commission's decision was still pending when we checked.[14]

The approved US indication, from the label: alongside a reduced-calorie diet and more physical activity, to reduce excess body weight and keep it down long term, in adults with obesity, or overweight with at least one weight-related condition. The label says not to use it together with another GLP-1 receptor agonist.[2]

What have the orforglipron trials found?

Every result below is from a peer-reviewed paper unless marked topline, meaning a Lilly press release not yet checked by a journal. The papers name the doses 6, 12 and 36 mg of the formulation used in the trials; the label reports the same trials under the tablet strengths sold, 5.5, 9 and 17.2 mg, with results that match the papers to within 0.1 point.[2]

Trial Who took part Length and doses Main result Status of the data
ATTAIN-1 3,127 adults with obesity or overweight, without diabetes 72 weeks; 6, 12 or 36 mg Body weight −7.5%, −8.4% and −11.2%, vs −2.1% on placebo[3] Peer-reviewed, NEJM, 2025
ATTAIN-2 1,613 adults with obesity or overweight and type 2 diabetes 72 weeks; 6, 12 or 36 mg Body weight −5.1%, −7.0% and −9.6%, vs −2.5%[15] Peer-reviewed, Lancet, 2025
ACHIEVE-1 559 adults with early type 2 diabetes 40 weeks; 3, 12 or 36 mg HbA1c −1.24, −1.47 and −1.48 points, vs −0.41; body weight −4.5%, −5.8% and −7.6%, vs −1.7%[16] Peer-reviewed, NEJM, 2025
ACHIEVE-3 1,698 adults with type 2 diabetes on metformin 52 weeks; orforglipron 12 or 36 mg vs oral semaglutide 7 or 14 mg, open-label HbA1c −1.71 and −1.91 points, vs −1.23 and −1.47 on semaglutide[9]; body weight −6.1% and −8.2%, vs −3.9% and −5.3% (topline)[17] Peer-reviewed, Lancet, 2026; weight figures topline
ATTAIN-MAINTAIN 376 adults who had reached a lower weight on tirzepatide or semaglutide injections 52 weeks; switched to orforglipron or placebo Share of the earlier reduction kept: 74.7% vs 49.2% after tirzepatide, 79.3% vs 37.6% after semaglutide[18] Peer-reviewed, Nature Medicine, 2026

In ATTAIN-1, 54.6% of people on 36 mg reached a reduction of at least 10% in body weight, against 12.9% on placebo, and 18.4% reached at least 20%, against 2.8%.[3] In ACHIEVE-3, both orforglipron doses lowered HbA1c more than both semaglutide doses, a result the authors found both non-inferior and superior.[9]

Lilly's own releases also report an "efficacy estimand", which estimates the effect in people who kept taking the drug and runs higher: in ATTAIN-1, −12.4% on 36 mg against −0.9% on placebo.[19] The peer-reviewed figures above are the more conservative ones.

How is orforglipron different from oral semaglutide?

The practical difference is the morning routine. Both semaglutide tablets, the Wegovy pill and Rybelsus, have the same strict instructions on their labels: take the tablet on an empty stomach in the morning with no more than 4 ounces of plain water, no other liquid, and wait at least 30 minutes before eating, drinking anything else or taking other oral medicines.[4][5]

The Foundayo label says only: "Take FOUNDAYO orally once daily, with or without food," swallowed whole.[2] It sets no water limit, no fasting period and no waiting time. Lilly's own wording, "any time of day without food or water restrictions," is marketing language, but it matches what the label leaves out.[20]

For anyone who takes a thyroid tablet, morning coffee or other medicines first thing, that is a real difference. Two other label points matter day to day:

  • Birth control pills. The label advises people using oral hormonal contraceptives to switch to a non-oral method, or add a barrier method, for 30 days after starting orforglipron and for 30 days after each dose increase.[2]
  • Some other medicines. The label limits the dose with strong CYP3A4 inhibitors, says to avoid some combinations, caps simvastatin at 20 mg a day, and suggests a lower insulin or sulfonylurea dose may be needed.[2] Your pharmacist can check your list.

Orforglipron side effects by dose

The pattern is the familiar one for this class: mostly digestive and rising with the dose. From the label's pooled data on 3,155 adults treated for up to 72 weeks:[2]

Reported event (label, Table 1) Placebo 5.5 mg 9 mg 17.2 mg
Nausea 10% 26% 34% 35%
Constipation 9% 20% 27% 24%
Diarrhea 11% 21% 23% 25%
Vomiting 4% 13% 21% 24%
Indigestion (dyspepsia) 4% 12% 16% 13%
Abdominal pain 7% 13% 14% 14%
Fatigue 4% 6% 7% 9%
Hair loss 2% 4% 4% 5%
Stopped the drug because of an adverse reaction 3% 6% 9% 10%

Any digestive adverse reaction was reported by 60% to 69% across the three doses, against 37% on placebo, and stopping for a digestive reaction by 3% to 6%, against 0.7%.[2] In the published ATTAIN-1 paper, 5.3% to 10.3% stopped for an adverse event, against 2.7% on placebo, and digestive events were mostly mild to moderate.[3]

Against oral semaglutide. In ACHIEVE-3, digestive adverse events were reported by 59% and 58% on orforglipron 12 and 36 mg, against 37% and 45% on semaglutide 7 and 14 mg, and 9% and 10% stopped orforglipron for an adverse event, against 4% and 5% on semaglutide.[9] The better HbA1c result came with more digestive events.

The label's warnings are those of the class: pancreatitis, severe digestive reactions, kidney injury from fluid loss, low blood sugar with insulin or sulfonylureas, gallbladder disease, allergic reactions, and the risk of inhaling stomach contents under anesthesia or deep sedation.[2] Anyone who cannot keep fluids down should call their prescriber. Food-first ideas for unsettled days are in what to eat on queasy days.

What the FDA label says about dosing

What the FDA label says — not dosing advice
Step Daily dose Label's minimum time before the next step
Start 0.8 mg 30 days
Step 2 2.5 mg 30 days
Step 3 5.5 mg 30 days; then increased only based on response and tolerability
Further steps, if used 9 mg, 14.5 mg, then 17.2 mg At least 30 days on each
Maximum 17.2 mg once daily —

Source: Foundayo prescribing information, sections 2.1 and 3.[2] The label also says not to take more than one tablet a day, and that after 7 or more missed doses in a row the dose is restarted lower. Your prescriber sets your dose.

How much does Foundayo cost?

As announced by Lilly at approval, self-pay starts at $149 a month for the lowest dose; people with commercial insurance that covers it may pay as little as $25 a month with Lilly's savings card; and Medicare Part D coverage at $50 a month was to begin as soon as July 1, 2026.[20] The highest dose was reported at $349 a month self-pay.[21] The federal TrumpRx site lists regular prices of $199 for 2.5 mg and $299 for 5.5 mg, both temporarily reduced through December 31, 2026.[22]

For comparison, Novo Nordisk's NovoCare page lists the Wegovy pill at $149 a month for 1.5 mg, $199 for 4 mg and $299 for 9 mg and 25 mg.[23] Prices change; check the maker's own page and your insurance before deciding anything. We could not read Lilly's own price page directly, so the Foundayo figures here are as reported on the dates shown in the references.

What does a daily pill mean for eating?

A pill that can be taken with breakfast removes one awkward rule, but the main eating problem of every GLP-1 medication stays: a smaller appetite. The 2025 joint advisory on nutrition with GLP-1 therapy sets out the priorities:[24]

  • Protein first. The advisory notes that 1.2 to 1.6 g of protein per kilogram of body weight a day has been proposed for adults on these medications, alongside strength training.[24] The numbers by body weight are in how much protein on a GLP-1, and the protein calculator splits a target into small meals.
  • Fluids on purpose. Normally about a fifth of the water people take in comes from food, so eating less quietly means drinking less too.[25] Vomiting and diarrhea, both in the table above, add to the loss. See how much water to drink on a GLP-1 and the hydration calculator.
  • Fiber and micronutrients. The advisory lists iron, calcium, magnesium, zinc and several vitamins as nutrients of concern when intake falls.[24] Constipation was reported by up to 27% in the label, so fiber and fluid matter; see how much fiber on a GLP-1 and the nutrition gap calculator.
  • Eat by the clock, not by hunger. The advisory suggests a reminder to eat when appetite is very low.[24] Soft, small options are in what to eat on a GLP-1 when you're not hungry.

The full map of these questions is our GLP-1 nutrition guide. If you are weighing an approved pill against a compounded product, read compounded semaglutide and tirzepatide first.

For transparency about why this page exists on our site: we make one product, Zornava Replenish, a lemon-lime daily hydration and nutrient powder for lighter appetite days, including for people on GLP-1 medications. It is a dietary supplement, not a medication, and it has nothing to do with orforglipron. It is not on sale yet; early access opens February 9, 2027, and the early-access list is open now.

Frequently asked questions

Is orforglipron FDA approved?

Yes. The FDA approved orforglipron as Foundayo on April 1, 2026, for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. As of November 13, 2026, its type 2 diabetes application, submitted in 2026, had no FDA decision.

What is the brand name of orforglipron?

Foundayo. It comes as once-daily tablets in six strengths, from 0.8 mg to 17.2 mg.

How is Foundayo different from the Wegovy pill?

Foundayo is a small molecule; the Wegovy pill is semaglutide, a peptide. The Wegovy pill must be taken on an empty stomach in the morning with up to 4 ounces of water and a 30-minute wait. Foundayo's label says to take it once daily with or without food, with no water limit. No head-to-head trial of the two for body weight has reported.

How well does orforglipron work?

In ATTAIN-1, a 72-week trial of 3,127 adults without diabetes, average body weight fell by 7.5%, 8.4% and 11.2% on 6, 12 and 36 mg, against 2.1% on placebo. In type 2 diabetes it lowered HbA1c more than oral semaglutide in the ACHIEVE-3 trial.

What are the most common side effects of orforglipron?

Nausea, constipation, diarrhea and vomiting. In the label's pooled data, nausea was reported by 26% to 35% across doses against 10% on placebo, and vomiting by 13% to 24% against 4%. Between 6% and 10% stopped the drug for an adverse reaction, against 3% on placebo.

Can you take orforglipron with food or coffee?

The label says to take it once daily "with or without food" and sets no water limit or waiting time. That is the main practical difference from the semaglutide tablets. Ask your pharmacist about your other medicines; the label lists some interactions, including with birth control pills.

How much does Foundayo cost without insurance?

Lilly announced self-pay pricing from $149 a month for the lowest dose, and the highest dose was reported at $349 a month. With commercial coverage, Lilly's savings card can bring it to $25 a month. Prices change, so check Lilly's own page.

Is orforglipron the same as Rybelsus?

No. Rybelsus is oral semaglutide from Novo Nordisk, approved for blood sugar control in type 2 diabetes, with the same empty-stomach rules as the Wegovy pill. Orforglipron is a different molecule from Eli Lilly. In ACHIEVE-3 it lowered HbA1c more than Rybelsus doses of semaglutide, with more digestive adverse events.

References

  1. US Food and Drug Administration. FDA Approves First New Molecular Entity Under National Priority Voucher Program. fda.gov. 2026. fda.gov. Press announcement of 2026-04-01. ↩︎
  2. Eli Lilly and Company. Foundayo (orforglipron) tablets, prescribing information. DailyMed, US National Library of Medicine. 2026. (sections 1, 2.1–2.3, 3, 5, 6.1 (Table 1), 7 and 14 (Table 6); revised July 2026) DailyMed. SPL read via DailyMed services (label effective 2026-07-29). ↩︎
  3. Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025;393(18):1796–1806. PubMed. PMID: 40960239. doi: 10.1056/NEJMoa2511774. ATTAIN-1. Abstract read (Europe PMC). Funded by Eli Lilly. ↩︎
  4. Novo Nordisk. Wegovy (semaglutide) injection and tablets, prescribing information and Medication Guide. DailyMed, US National Library of Medicine. 2026. (section 2.1, Wegovy tablets) DailyMed. ↩︎
  5. Novo Nordisk. Rybelsus and Ozempic (semaglutide) tablets, prescribing information and Medication Guide. DailyMed, US National Library of Medicine. 2026. (sections 1 and 2.1) DailyMed. SPL read via DailyMed services (label effective 2026-01-30). ↩︎
  6. Eli Lilly and Company. Lilly reports second-quarter 2026 financial results, raises full-year guidance and highlights continued growth and pipeline progress. Press release (via BioSpace). 2026. biospace.com. Press release of 2026-08-05; lists the US submission for type 2 diabetes. ↩︎
  7. Novo Nordisk. Press release (PR Newswire). 2025. prnewswire.com. Press release of 2025-12-22. ↩︎
  8. Wharton S, Lingvay I, Bogdanski P, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med. 2025;393(11):1077–1087. PubMed. PMID: 40934115. doi: 10.1056/NEJMoa2500969. OASIS 4. Abstract read (placebo −2.2% in the paper; the label reports −2.4%). Funded by Novo Nordisk. ↩︎
  9. Rosenstock J, Yabe D, Cox D, et al. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet. 2026;407(10534):1147–1160. PubMed. PMID: 41765029. doi: 10.1016/S0140-6736(26)00202-3. Abstract read (Europe PMC). Funded by Eli Lilly. ↩︎
  10. Eli Lilly and Company. Zepbound (tirzepatide) injection, prescribing information and Medication Guide. DailyMed, US National Library of Medicine. 2026. DailyMed. ↩︎
  11. US Food and Drug Administration. FDA Awards Second Batch of National Priority Vouchers. fda.gov. 2025. fda.gov. Press announcement of 2025-11-06. ↩︎
  12. Eli Lilly and Company. Press release (via Seeking Alpha). 2025. seekingalpha.com. Press release of 2025-12-18, read as reproduced on Seeking Alpha (Lilly's site refuses scripted requests). States the obesity NDA had been submitted. ↩︎
  13. Medicines and Healthcare products Regulatory Agency. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes. gov.uk. 2026. gov.uk. News story of 2026-08-10. ↩︎
  14. European Medicines Agency. New oral GLP-1 medicine for weight management and type 2 diabetes. ema.europa.eu. 2026. ema.europa.eu. News item of 2026-10-16 (CHMP positive opinion; European Commission decision pending). ↩︎
  15. Horn DB, Ryan DH, Kis SG, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2025;406(10522):2927–2944. PubMed. PMID: 41275875. doi: 10.1016/S0140-6736(25)02165-8. Abstract read (Europe PMC). Funded by Eli Lilly. ↩︎
  16. Rosenstock J, Hsia S, Nevarez Ruiz L, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. N Engl J Med. 2025;393(11):1065–1076. PubMed. PMID: 40544435. doi: 10.1056/NEJMoa2505669. ACHIEVE-1. Abstract read (Europe PMC). Funded by Eli Lilly. ↩︎
  17. Eli Lilly and Company. Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial. Press release (PR Newswire, via BioSpace). 2025. biospace.com. Press release of 2025-09-17. Company-reported topline results. ↩︎
  18. Aronne LJ, Horn DB, le Roux CW, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026;32(7):2679–2687. PubMed. PMID: 42120723. doi: 10.1038/s41591-026-04386-7. Abstract read (Europe PMC). Funded by Eli Lilly. ↩︎
  19. Patient Care. Patient Care. 2025. patientcareonline.com. Trade-press report of Lilly's ATTAIN-1 topline release of 2025-08-07 (efficacy estimand). Company-reported. ↩︎
  20. Eli Lilly and Company. Press release (PR Newswire, via BioSpace). 2026. (pricing and access as announced April 1, 2026) biospace.com. Press release of 2026-04-01. Company statements on pricing and access. ↩︎
  21. Vinluan F (MedCity News). Eli Lilly Gets Speedy FDA Nod for Oral GLP-1 Drug, a Competitor to New Novo Nordisk Pill. MedCity News. 2026. medcitynews.com. News report of 2026-04-01; the $349 highest-dose price is attributed to a UBS analyst note. ↩︎
  22. US Department of Health and Human Services. Foundayo. TrumpRx.gov. 2026. trumprx.gov. Federal price listing read 2026-11-13; 2.5 mg and 5.5 mg temporarily reduced through 2026-12-31 (reduced amounts not shown). ↩︎
  23. Novo Nordisk. Wegovy: savings and self-pay options. novocare.com. 2026. novocare.com. Manufacturer's page; self-pay prices for Wegovy tablets read 2026-11-13. ↩︎
  24. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring). 2025;33(8):1475–1503. (sections on low appetite, protein, fluids and nutrients of concern) Full text. PMID: 40445127. doi: 10.1002/oby.24336. ↩︎
  25. Institute of Medicine. Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate. National Academies Press. 2005. nap.nationalacademies.org. doi: 10.17226/10925. ↩︎
Share this
← All Lighter Days articles

Free guide

The GLP-1 eating plan

Eight pages to print and keep, built protein first for days when appetite is small. Sourced, like everything on Lighter Days.

  • Seven days of four small meals, with protein and fiber counted
  • A food list: what to eat more often, and what to go easy on
  • A shopping list and a page to take to your prescriber or dietitian

You’ll also get early access to Replenish and a few emails a month. Unsubscribe any time.